Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-MILs
- Development stage
- Preclinical
- Lead developer
- WindMIL Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
**CAR-MILs** is an autologous engineered cell therapy platform developed by WindMIL Therapeutics that uses a patient's marrow-infiltrating lymphocytes expanded from bone marrow and genetically modified to express a chimeric antigen receptor. In multiple myeloma and potentially other cancers, CAR-MILs are designed to combine the antigen-directed killing of CAR technology with the endogenous polyclonal tumor reactivity of marrow-infiltrating lymphocytes, which may provide dual tumor recognition, memory-like T-cell properties, and enhanced persistence relative to conventional peripheral-blood-derived CAR-T approaches. The platform has been described with constructs such as BCMA-directed and CD38-directed CARs and remains an investigational biologic cell therapy.
- Other names
- CAR-modified Marrow-Infiltrating Lymphocytes
02
Targets
BCMA (B-cell maturation antigen)CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on CAR-MILs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-MILs.